Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.

[1]  M W Kattan,et al.  Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma , 2001, Cancer.

[2]  D. Erickson.  Urine markers of interstitial cystitis. , 2001, Urology.

[3]  P. Sale,et al.  Heat shock protein-90, IL-6 and IL-10 in bladder cancer. , 2000, Anticancer Research.

[4]  S. Kitazawa,et al.  Independent prognostic value of serum hepatocyte growth factor in bladder cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Horn,et al.  Interleukin-6 signal transduction and lymphocyte function. , 2000, Immunobiology.

[6]  W. Fair,et al.  Radical Cystectomy for Invasive Bladder Cancer: Contemporary Results and Remaining Controversies , 2000, European Urology.

[7]  Y. Horiguchi,et al.  Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  J. Heath,et al.  Receptor recognition by gp130 cytokines , 2000, The EMBO journal.

[9]  J. Jessup,et al.  Interleukin-6 Blood Level Is Associated With Circulating Carcinoembryonic Antigen and Prognosis in Patients With Colorectal Cancer , 2000, Annals of Surgical Oncology.

[10]  M. Yaron,et al.  Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis , 2000, Rheumatology International.

[11]  C. Miki,et al.  Serum interleukin‐6 level reflects the tumor proliferative activity in patients with colorectal carcinoma , 1999, Cancer.

[12]  J. Simons,et al.  Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.

[13]  Kanetake,et al.  Systemic immune response after intravesical instillation of bacille Calmette–Guérin (BCG) for superficial bladder cancer , 1999, Clinical and experimental immunology.

[14]  M. Kattan,et al.  Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. , 1999, The Journal of urology.

[15]  S. Akimoto,et al.  Relationship between serum levels of interleukin-6, tumor necrosis factor-alpha and bone turnover markers in prostate cancer patients. , 1998, Endocrine journal.

[16]  M. Housset,et al.  Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Oyasu,et al.  Interleukin‐6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro , 1997, International journal of cancer.

[18]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[19]  M. Nakajima,et al.  Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. , 1996, Cancer research.

[20]  S. Prescott,et al.  Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. , 1995, The Journal of urology.

[21]  C. Peschle,et al.  Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. , 1995, British Journal of Cancer.

[22]  S. Groshen,et al.  The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. , 1993, The Journal of urology.

[23]  R. Kerbel,et al.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression [published erratum appears in J Cell Biol 1993 Apr;121(2):following 477] , 1993, The Journal of cell biology.

[24]  A. Okuyama,et al.  Interleukin-6 activity in urine and serum in patients with bladder carcinoma. , 1992, The Journal of urology.

[25]  T. Hirano,et al.  Enhanced expression of interleukin-6 in primary human renal cell carcinomas. , 1991, Journal of the National Cancer Institute.

[26]  L. Sachs,et al.  Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Sehgal,et al.  Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells , 1989, The Journal of experimental medicine.